Zydus Lifesciences has secured final approval from the US Food and Drug Administration (USFDA) for its generic version of dapagliflozin, a medication aimed at managing type 2 diabetes mellitus. Available in 5 mg and 10 mg strengths, this drug is prescribed to enhance blood sugar control in adults, alongside diet and exercise. Dapagliflozin belongs to the class of SGLT2 inhibitors, which facilitate the kidneys in expelling excess glucose through urine, thereby reducing blood sugar levels independently of insulin. The World Health Organization (WHO) emphasizes the importance of such medications, as diabetes elevates the risk of heart disease and kidney damage. Clinical studies have indicated that dapagliflozin not only aids in blood sugar management but also provides protective benefits for heart health and slows the progression of chronic kidney disease. The US market for dapagliflozin tablets has seen annual sales of $10.2 billion, highlighting the demand for effective diabetes treatments. The approval grants Zydus 180 days of shared exclusivity, potentially enhancing drug affordability and access for patients. However, it is essential for patients to consult healthcare providers before starting the medication, as it may cause side effects such as urinary tract infections and dehydration.